Src - SRC proto-oncogene, non-receptor tyrosine kinase Gene

中文名称：SRC 原癌基因，非受体酪氨酸激酶

种属: Rattus norvegicus

基因 ID: 83805 | 基因类型: protein coding

关于 Src

Primary_assembly 3: 146,091,841-146,139,476 forward strand.mRatBN7.2:CM026976.1

This gene has 2 transcripts (splice variants), 261 orthologues, 32 paralogues and is associated with 42 phenotypes. Biased expression in Brain (RPKM 86.6), Lung (RPKM 78.5) and 9 other tissues.

功能概要

该基因编码的蛋白可启动多种功能，包括雌激素受体结合活性；胰岛素受体结合活性；和蛋白质 C 末端结合活性。参与多个过程，包括细胞对脂质的反应；磷酸化的正调控；和信号转导的调节。位于caveola;神经元投射；和突触后密度。活跃于谷氨酸能突触和突触后特化，细胞内成分。用于研究帕金森症；脑缺血;高血压;癫痫持续状态；和 2 型糖尿病。该基因与结直肠癌相关的人类直系同源物（多个）；导管原位癌；前列腺癌;血小板减少症;和 2 型糖尿病。与人类 Src 同源（SRC 原癌基因，非受体酪氨酸激酶）。 [由基因组资源联盟提供，2022 年 4 月]

Enables several functions, including Estrogen Receptor binding activity; Insulin Receptor binding activity; and protein C-terminus binding activity. Involved in several processes, including cellular response to lipid; positive regulation of phosphorylation; and regulation of signal transduction. Located in caveola; neuron projection; and postsynaptic density. Is active in glutamatergic synapse and postsynaptic specialization, intracellular component. Used to study Parkinsonism; brain ischemia; hypertension; status epilepticus; and type 2 diabetes mellitus. Human ortholog(s) of this gene implicated in colorectal Cancer (multiple); ductal carcinoma in situ; prostate cancer; thrombocytopenia; and type 2 diabetes mellitus. Orthologous to human Src (Src proto-oncogene, non-receptor tyrosine kinase). [provided by Alliance of Genome Resources, Apr 2022]

Src 基因产物(1)

mRNA	Protein	Name
NM_031977.1	NP_114183.1	proto-oncogene tyrosine-protein kinase Src

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables cell adhesion molecule binding	IPI IPI: 通过物理相互作用推断	19948503	RGD
enables enzyme binding	IPI IPI: 通过物理相互作用推断	15069201	RGD
enables insulin receptor binding	IPI IPI: 通过物理相互作用推断	19952103	RGD
enables nuclear estrogen receptor binding	IPI IPI: 通过物理相互作用推断	14751567	RGD
enables protein binding	IPI IPI: 通过物理相互作用推断	8849729	RGD
enables protein kinase C binding	IPI IPI: 通过物理相互作用推断	14751567	RGD
enables protein kinase binding	IPI IPI: 通过物理相互作用推断	12700184	RGD
enables protein tyrosine kinase activity	IDA IDA: 通过直接分析推断	8849729	RGD
enables protein-containing complex binding	IPI IPI: 通过物理相互作用推断	12618293	RGD
enables signaling receptor binding	IPI IPI: 通过物理相互作用推断	11478920	RGD
enables transmembrane transporter binding	IPI IPI: 通过物理相互作用推断	11834728	RGD

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in DNA biosynthetic process	IMP IMP: 通过突变表型推断	9227431	RGD
involved in adherens junction organization	IEP IEP: 通过表达模式推断	15389520	RGD
involved in cell-cell adhesion	IEP IEP: 通过表达模式推断	15591141	RGD
involved in cellular response to angiotensin	IEP IEP: 通过表达模式推断	7586216	RGD
involved in cellular response to fatty acid	IEP IEP: 通过表达模式推断	20149623	RGD
involved in cellular response to hydrogen peroxide	IEP IEP: 通过表达模式推断	8807585	RGD
involved in cellular response to hypoxia	IEP IEP: 通过表达模式推断	20380727	RGD
involved in cellular response to insulin stimulus	IEP IEP: 通过表达模式推断	19952103	RGD
involved in cellular response to lipopolysaccharide	IEP IEP: 通过表达模式推断	20149623	RGD
involved in cellular response to platelet-derived growth factor stimulus	IEP IEP: 通过表达模式推断	11417999	RGD
involved in cellular response to progesterone stimulus	IMP IMP: 通过突变表型推断	21440892	RGD
involved in cellular response to prolactin	IEP IEP: 通过表达模式推断	8584023	RGD
involved in epidermal growth factor receptor signaling pathway	IEP IEP: 通过表达模式推断	15856020	RGD
involved in learning or memory	IEP IEP: 通过表达模式推断	10884433	RGD
involved in myoblast proliferation	IEP IEP: 通过表达模式推断	2425941	RGD
involved in negative regulation of focal adhesion assembly	IMP IMP: 通过突变表型推断	21440892	RGD
involved in negative regulation of gene expression	IMP IMP: 通过突变表型推断	16530387	RGD
involved in neurotrophin TRK receptor signaling pathway	IDA IDA: 通过直接分析推断	15546918	RGD
involved in peptidyl-tyrosine autophosphorylation	IMP IMP: 通过突变表型推断	18583343	RGD
involved in platelet-derived growth factor receptor signaling pathway	IEP IEP: 通过表达模式推断	16530387	RGD
involved in positive regulation of ERK1 and ERK2 cascade	IMP IMP: 通过突变表型推断	16530387	RGD
involved in positive regulation of MAP kinase activity	IMP IMP: 通过突变表型推断	11941412	RGD
involved in positive regulation of Ras protein signal transduction	IMP IMP: 通过突变表型推断	8626602	RGD
involved in positive regulation of apoptotic process	IDA IDA: 通过直接分析推断	15322113	RGD
involved in positive regulation of bone resorption	IMP IMP: 通过突变表型推断	8514886	RGD
involved in positive regulation of cell adhesion	IDA IDA: 通过直接分析推断	15735685	RGD
involved in positive regulation of cell population proliferation	IMP IMP: 通过突变表型推断	16530387	RGD
involved in positive regulation of cytokine production	IMP IMP: 通过突变表型推断	19736311	RGD
involved in positive regulation of gene expression	IMP IMP: 通过突变表型推断	16530387	RGD
involved in positive regulation of glucose metabolic process	IMP IMP: 通过突变表型推断	19230846	RGD
involved in positive regulation of insulin receptor signaling pathway	IDA IDA: 通过直接分析推断	14985360	RGD
involved in positive regulation of intracellular signal transduction	IMP IMP: 通过突变表型推断	19713443	RGD
involved in positive regulation of male germ cell proliferation	IMP IMP: 通过突变表型推断	18560731	RGD
involved in positive regulation of ovarian follicle development	IMP IMP: 通过突变表型推断	22905678	RGD
involved in positive regulation of peptidyl-tyrosine phosphorylation	IMP IMP: 通过突变表型推断	9227431	RGD
involved in positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	IMP IMP: 通过突变表型推断	16530387	RGD
involved in positive regulation of protein transport	IMP IMP: 通过突变表型推断	15007081	RGD
involved in positive regulation of smooth muscle cell migration	IMP IMP: 通过突变表型推断	19736311	RGD
involved in positive regulation of vascular associated smooth muscle cell proliferation	IMP IMP: 通过突变表型推断	9227431	RGD
involved in primary ovarian follicle growth	IMP IMP: 通过突变表型推断	22905678	RGD
involved in progesterone receptor signaling pathway	IMP IMP: 通过突变表型推断	21440892	RGD
involved in response to acidic pH	IEP IEP: 通过表达模式推断	12081562	RGD
involved in response to electrical stimulus	IEP IEP: 通过表达模式推断	20356829	RGD
involved in response to fatty acid	IEP IEP: 通过表达模式推断	19736311	RGD
involved in response to hydrogen peroxide	IEP IEP: 通过表达模式推断	12226102	RGD
involved in response to mechanical stimulus	IEP IEP: 通过表达模式推断	15731459	RGD
involved in response to mineralocorticoid	IEP IEP: 通过表达模式推断	16157790	RGD
involved in response to nutrient levels	IEP IEP: 通过表达模式推断	20357031	RGD
involved in response to xenobiotic stimulus	IEP IEP: 通过表达模式推断	20149623	RGD
involved in skeletal muscle cell proliferation	IEP IEP: 通过表达模式推断	2447874	RGD
involved in spermatogenesis	IEP IEP: 通过表达模式推断	7530000	RGD
involved in transcytosis	IDA IDA: 通过直接分析推断	15007081	RGD

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in caveola	IDA IDA: 通过直接分析推断	20167931	RGD
located in dendritic filopodium	IDA IDA: 通过直接分析推断	2462872	RGD
located in dendritic growth cone	IDA IDA: 通过直接分析推断	2462872	RGD
is active in glutamatergic synapse	EXP EXP: 通过实验结果推断	9005855	RGD
is active in glutamatergic synapse	IDA IDA: 通过直接分析推断	9005855	RGD
located in neuronal cell body	IDA IDA: 通过直接分析推断	2462872	RGD
is active in postsynaptic specialization, intracellular component	IDA IDA: 通过直接分析推断	14529711	RGD
located in synaptic membrane	IDA IDA: 通过直接分析推断	10884433	RGD

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Src 蛋白结构

SH3_Src

SH2_Src_Src

PTKc_Src

0
100
200
300
400
500
542 a.a.

蛋白主名

其他名称

proto-oncogene tyrosine-protein kinase Src

Rous sarcoma oncogene	c-Src
p60-Src	pp60c-src
proto-oncogene c-Src	tyrosine protein kinase c-src
tyrosine protein kinase pp60-c-src	v-src avian sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog
v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog

Src 蛋白互作信息

分类	蛋白名称	蛋白编号	互作蛋白	互作蛋白种属	互作蛋白编号	实验方法	参考文献
种属内	Src	Q9WUD9	Cacna1c	Rattus norvegicus	P22002	Pull Down	16352297
种属内	Src	Q9WUD9	Cd63	Rattus norvegicus	P28648	Anti Bait CoIP	18211905
种属内	Src	Q9WUD9	Ptprr	Rattus norvegicus	O08617	Pull Down	12526090
种属内	Src	Q9WUD9	Ptprr	Rattus norvegicus	O08617	Anti Bait CoIP	12526090
种属间	Src	Q9WUD9	PTPN1	Homo sapiens	P18031	Pull Down	12023880

种属间: 跨种属相互作用 种属内: 同种属相互作用

相关产品

Approval

生物活性分子 (10)

目录号	产品名	作用方式	纯度	是否罕见病
HY-10181	Dasatinib	Inhibitor	99.88%	是
HY-12047	Ponatinib	Inhibitor	99.67%	是
HY-10158	Bosutinib	Inhibitor	99.96%	是
HY-10209	Masitinib	Inhibitor	99.98%	是
HY-10181A	Dasatinib hydrochloride	Inhibitor	99.67%	是
HY-108766	Ponatinib hydrochloride	Inhibitor	99.55%	是
HY-10209A	Masitinib mesylate	Inhibitor	99.83%	是
HY-10340B	Tirbanibulin Mesylate	Inhibitor	99.94%	否
HY-10181B	Dasatinib monohydrate	Inhibitor	98.48%	是
HY-10158A	Bosutinib hydrate	Inhibitor	99.97%	是

Clinical Phase

生物活性分子 (17)

目录号	产品名	作用方式	纯度	Phase
HY-10234	Saracatinib	Inhibitor	99.92%	Phase 3
HY-10340	Tirbanibulin	Inhibitor	99.56%	Phase 3
HY-13314	Tesevatinib	Inhibitor	99.21%	Phase 3
HY-10340A	Tirbanibulin dihydrochloride	Inhibitor	99.59%	Phase 3
HY-13024	Rebastinib	Inhibitor	99.91%	Phase 2
HY-50868	Bafetinib	Inhibitor	99.77%	Phase 2
HY-15323	PRT062607 Hydrochloride	Inhibitor	98.07%	Phase 2
HY-59047	Tolimidone	Activator	99.93%	Phase 2
HY-32718	Pelitinib	Inhibitor	98.80%	Phase 2
HY-111787	Elzovantinib	Inhibitor	99.93%	Phase 2
HY-10987A	ENMD-2076	Inhibitor	99.12%	Phase 2
HY-10987	ENMD-2076 Tartrate	Inhibitor	99.42%	Phase 2
HY-10186	TG 100801	Inhibitor	98.61%	Phase 2
HY-10187	TG 100801 Hydrochloride	Inhibitor	/	Phase 2
HY-15749	XL228	Inhibitor	99.64%	Phase 1
HY-112809	GSK2646264	Inhibitor	98.39%	Phase 1
HY-112314	AZD0424	Inhibitor	/	Phase 1

Pre-clinical Phase

生物活性分子 (147)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-13805	PP2	Inhibitor	98.34%	否
HY-12299	WH-4-023	Inhibitor	99.75%	否
HY-B0789	SU6656	Inhibitor	98.30%	否
HY-N0752	Scutellarein	Inhibitor	99.25%	否
HY-112096	eCF506	Inhibitor	99.77%	否
HY-12072	Lck Inhibitor	Inhibitor	99.45%	否
HY-15764A	A 419259 trihydrochloride	Inhibitor	99.21%	否
HY-101053	Src Inhibitor 1	Inhibitor	99.93%	否
HY-13942	1-NM-PP1	Inhibitor	99.17%	否
HY-136848	SM1-71	Inhibitor	96.09%	否
HY-13804	PP1	Inhibitor	99.00%	否
HY-135299	CH6953755	Inhibitor	99.45%	否
HY-W062835	CGP77675	Inhibitor	99.00%	否
HY-130254	CSK-IN-1	Inhibitor	98.61%	否
HY-13941	1-Naphthyl PP1	Inhibitor	99.08%	否
HY-11011	A-770041	Inhibitor	99.95%	否
HY-10032	PF 477736	Inhibitor	99.21%	否
HY-15764	A 419259	Inhibitor	99.75%	否
HY-112852	TL02-59	Inhibitor	99.84%	否
HY-10395	PD173955	Inhibitor	99.12%	否
HY-139147	iHCK-37	Inhibitor	99.52%	否
HY-N0202	Atractylenolide II	Inhibitor	99.94%	否
HY-18303	AMG-47a	Inhibitor	99.34%	否
HY-10372	PP121	Inhibitor	98.67%	否
HY-78263	MNS	Inhibitor	99.55%	否
HY-155657	BT424	Inhibitor	98.81%	否
HY-112182	UM-164	Inhibitor	99.15%	否
HY-108318	RK-24466	Inhibitor	98.53%	否
HY-P3279	EPQpYEEIPIYL	Activator	99.62%	否
HY-122113	PD173952	Inhibitor	99.44%	否
HY-13561	AZM475271	Inhibitor	99.85%	否
HY-101963	AD80	Inhibitor	99.88%	否
HY-18622	PP58	Inhibitor	99.75%	否
HY-10644	Lck inhibitor 2	Inhibitor	99.81%	否
HY-163144	DAS-5-oCRBN	Degrader	98.75%	否
HY-136605	DGY-06-116	Inhibitor	99.54%	否
HY-120213	YH-306	Inhibitor	98.34%	否
HY-107024	Osteogenic Growth Peptide (10-14)	Inhibitor	99.77%	否
HY-P1377A	Caffeic acid-pYEEIE TFA		98.47%	否
HY-100434	PD-161570	Inhibitor	99.82%	否
HY-108485	Damnacanthal	Inhibitor	≥98.0%	否
HY-10185	TG 100572 Hydrochloride	Inhibitor	98.96%	否
HY-108488	KB SRC 4	Inhibitor	99.66%	否
HY-13941B	1-Naphthyl PP1 hydrochloride	Inhibitor	99.83%	否
HY-N4127	3'-Demethylnobiletin		99.98%	否
HY-118144	PD166326	Inhibitor	99.99%	否
HY-127002	Squarunkin A	Inhibitor	99.34%	否
HY-103274	PD180970	Inhibitor	99.27%	否
HY-153556	GW297361	Inhibitor	98.13%	否
HY-159480	AD1058	Inhibitor	98.11%	否
HY-10181S	Dasatinib-d8	Inhibitor	98.17%	否
HY-15805	KIN-8194	Inhibitor	98.01%	否
HY-N4201	β-Hydroxyisovalerylshikonin	Inhibitor	99.83%	否
HY-132150A	HPK1-IN-2 dihydrochloride	Inhibitor	98.69%	否
HY-120595	JNJ-49095397	Inhibitor	99.85%	否
HY-112345	PD-089828	Inhibitor	98.07%	否
HY-108016	Peruvoside	Inhibitor	99.32%	否
HY-18237	KX1-004	Inhibitor	99.75%	否
HY-10234A	Saracatinib difumarate	Inhibitor	99.24%	是
HY-W013857	Lavendustin C	Inhibitor	98.32%	否
HY-123506	Fenlean	Inhibitor	99.56%	否
HY-125028	Hck-IN-1	Inhibitor	98.53%	否
HY-15764G	A 419259 (GMP)	Inhibitor	/	否
HY-15324	PRT062607 acetate	Inhibitor	99.83%	否
HY-10158S	Bosutinib-d8	Inhibitor	≥99.0%	否
HY-112291	SB 220025	Inhibitor	99.90%	否
HY-N6596	7-Hydroxy-4H-chromen-4-one	Inhibitor	99.94%	否
HY-116028	15-deoxy-Δ12,14-Prostaglandin D2	Activator	≥98.0%	否
HY-13342AS	Apatinib-d8 free base		92.56%	否
HY-15814	HG-7-85-01	Inhibitor	99.94%	否
HY-18507	AD57	Inhibitor	98.08%	否
HY-W744699	Larixol	Inhibitor	95.52%	否
HY-12047S	Ponatinib-d8	Inhibitor	99.91%	否
HY-111187	KX2-361	Inhibitor	99.55%	否
HY-138202	Lck-IN-1	Inhibitor	99.6%	否
HY-16905	T338C Src-IN-1	Inhibitor	/	否
HY-16906	T338C Src-IN-2	Inhibitor	/	否
HY-N7160	2-Hydroxy-3-methylanthraquinone	Inhibitor	99.60%	否
HY-10184	TG 100572	Inhibitor	/	否
HY-118105	RK-20448	Inhibitor	99.38%	否
HY-112852A	TL02-59 dihydrochloride	Inhibitor	/	否
HY-157998	mG2N001		/	否
HY-125387	TOP1210		/	否
HY-128397	CpCDPK1/TgCDPK1-IN-1	Inhibitor	/	否
HY-100824	PP2 Analog	Inhibitor	/	否
HY-163278	Lck-IN-2	Inhibitor	/	否
HY-P1200A	Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH TFA	Inhibitor	/	否
HY-W062835A	CGP77675 hydrate	Inhibitor	/	否
HY-W745090	Isomaltulose monohydrate	Inhibitor	/	否
HY-123298	Chrysotoxine	Inhibitor	/	否
HY-162413	(R)-LW-Srci-8	Inhibitor	/	否
HY-112335	Lck Inhibitor III	Inhibitor	/	否
HY-121849	KL-1156	Inhibitor	/	否
HY-P10527	CSK substrate		/	否
HY-P1111A	Lyn peptide inhibitor TFA	Inhibitor	/	否
HY-115723	Antiallergic agent-1	Inhibitor	/	否
HY-P10665	pYEEI	Inhibitor	/	否
HY-146014	Multi-kinase-IN-1	Inhibitor	/	否
HY-161687	Cisplatin/Dasatinib prodrug-1	Inhibitor	/	否
HY-P3773	p60c-src substrate II		/	否
HY-12847	CCT241161	Inhibitor	/	否
HY-162291	Lck-IN-3	Inhibitor	/	否
HY-163469	SRC-3-IN-2	Inhibitor	/	否
HY-127002A	Squarunkin A hydrochloride	Inhibitor	/	否
HY-10363	AP 24149	Inhibitor	/	否
HY-102073	TG53	Inhibitor	/	否
HY-P3743	p60c-src Substrate		/	否
HY-139890	DC-Srci-6649	Inhibitor	/	否
HY-13314A	Tesevatinib tosylate	Inhibitor	/	否
HY-112096S	eCF506-d5	Inhibitor	/	否
HY-P1111	Lyn peptide inhibitor	Inhibitor	/	否
HY-P1784	Secretin, canine		/	否
HY-10181G	Dasatinib (GMP)	Inhibitor	/	否
HY-157497	DA5-HTL	Inhibitor	/	否
HY-101268	CHMFL-ABL-053	Inhibitor	/	否
HY-110367	LCB 03-0110 dihydrochloride	Inhibitor	/	否
HY-168187	Src Inhibitor 3	Inhibitor	/	否
HY-101447	SI-2	Inhibitor	/	否
HY-156914	IGF-1R/SRC-IN-1	Inhibitor	99.86%	否
HY-P2547	Tyrosine Kinase Peptide 1		/	否
HY-112393	TX-1918	Inhibitor	/	否
HY-18507A	AD57 hydrochloride	Inhibitor	/	否
HY-162676	SJ45566	Degrader	/	否
HY-P10372	pFYN peptide		/	否
HY-163468	SRC-3-IN-1	Inhibitor	/	否
HY-110367A	LCB 03-0110	Inhibitor	/	否
HY-P0200	RR-SRC		/	否
HY-121828	TX-1123	Inhibitor	/	否
HY-162879	FAK inhibitor 7	Inhibitor	/	否
HY-157290	HL403	Inhibitor	/	否
HY-P1200	Ac-Tyr(PO3H2)-Glu-Glu-Ile-Glu-OH	Inhibitor	/	否
HY-135216	Antiproliferative agent-54	Inhibitor	/	否
HY-15268	PP487	Inhibitor	/	否
HY-150026	Multi-kinase-IN-2	Inhibitor	/	否
HY-147314	HIV-IN-6		98.35%	否
HY-10234S	Saracatinib-d3	Inhibitor	/	否
HY-160930	TOP1288	Inhibitor	/	否
HY-125064	AP22408	Inhibitor	/	否
HY-120622	BMS-243117	Inhibitor	/	否
HY-164530	SKLB646	Inhibitor	/	否
HY-122585	proMMP-9 inhibitor-3c	Inhibitor	/	否
HY-112291A	SB 220025 (tri(hydrochloride))	Inhibitor	/	否
HY-164527	Si306	Inhibitor	/	否
HY-10181S1	Dasatinib-d4	Inhibitor	/	否
HY-W700620	Hydroxymethyl dasatinib	Inhibitor	99.92%	否
HY-N12166	2,3,4,6,8-Pentahydroxy-1-methylxanthone	Inhibitor	/	否
HY-P1377	Caffeic acid-pYEEIE		/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Src	NCBI	NCBI:6714
Mus musculus	Src	NCBI	NCBI:20779

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.